Madhawi gained her experience in obesity, eating behaviour, and mechanisms of weight loss at Imperial College, London during her work in the Endobarrier® RCT, for a duodenal sleeve bypass device added to intensive medical therapy for obesity with type 2 diabetes (2016–2020). Concurrently, she was assigned as a clinical trial coordinator in the international randomised clinical trial, Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) (2018-2020), Imperial College, London. During her Ph.D. studies, she participated as a co-investigator in the GRAVITAS trial (Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery: A randomised, double-blind, placebo-controlled trial), which was published in a high-impact-factor journal (2019). Meanwhile, on her return to King Saud University, she worked on investigating the impact of liraglutide on eating behaviour and taste function, and the impact of precautionary lockdown measures during COVID-19 on eating behaviour and lifestyle.